CY1118503T1 - Αντιμικροβιακο πεπτιδιο και συνθεσεις αυτου - Google Patents

Αντιμικροβιακο πεπτιδιο και συνθεσεις αυτου

Info

Publication number
CY1118503T1
CY1118503T1 CY20161101296T CY161101296T CY1118503T1 CY 1118503 T1 CY1118503 T1 CY 1118503T1 CY 20161101296 T CY20161101296 T CY 20161101296T CY 161101296 T CY161101296 T CY 161101296T CY 1118503 T1 CY1118503 T1 CY 1118503T1
Authority
CY
Cyprus
Prior art keywords
compositions
present
hiv
gram
skin
Prior art date
Application number
CY20161101296T
Other languages
Greek (el)
English (en)
Inventor
Hongran Fan Stone
Jacob M Waugh
Original Assignee
Revance Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeutics, Inc. filed Critical Revance Therapeutics, Inc.
Publication of CY1118503T1 publication Critical patent/CY1118503T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CY20161101296T 2007-07-26 2016-12-14 Αντιμικροβιακο πεπτιδιο και συνθεσεις αυτου CY1118503T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95205907P 2007-07-26 2007-07-26
PCT/US2008/071350 WO2009015385A1 (en) 2007-07-26 2008-07-28 Antimicrobial peptide, compositions , and methods of use

Publications (1)

Publication Number Publication Date
CY1118503T1 true CY1118503T1 (el) 2017-07-12

Family

ID=40281862

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161101296T CY1118503T1 (el) 2007-07-26 2016-12-14 Αντιμικροβιακο πεπτιδιο και συνθεσεις αυτου
CY20201100692T CY1123176T1 (el) 2007-07-26 2020-07-27 Antimikpobiako πεπτιδιο και συνθεσεις αυτου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100692T CY1123176T1 (el) 2007-07-26 2020-07-27 Antimikpobiako πεπτιδιο και συνθεσεις αυτου

Country Status (24)

Country Link
US (1) US8623811B2 (enExample)
EP (3) EP3741380A1 (enExample)
JP (5) JP5401457B2 (enExample)
KR (4) KR101717275B1 (enExample)
CN (2) CN101842107B (enExample)
AU (1) AU2008278593B2 (enExample)
BR (3) BR122019000258B1 (enExample)
CA (1) CA2694046C (enExample)
CO (1) CO6260098A2 (enExample)
CR (1) CR11239A (enExample)
CY (2) CY1118503T1 (enExample)
DK (2) DK2178549T3 (enExample)
ES (2) ES2805225T3 (enExample)
HR (1) HRP20161722T1 (enExample)
HU (1) HUE031136T2 (enExample)
IL (3) IL203173A (enExample)
LT (1) LT2178549T (enExample)
MX (1) MX2010000916A (enExample)
NZ (1) NZ582459A (enExample)
PL (1) PL2178549T3 (enExample)
PT (2) PT3120862T (enExample)
SG (1) SG188128A1 (enExample)
SI (1) SI2178549T1 (enExample)
WO (1) WO2009015385A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
ES2805225T3 (es) * 2007-07-26 2021-02-11 Revance Therapeutics Inc Péptidos antimicrobianos y composiciones de los mismos
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
EP3031825B1 (en) 2008-03-14 2019-07-24 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
EP3332805B1 (en) * 2008-12-31 2022-02-23 ReVance Therapeutics, Inc. Injectable botulinum toxin formulations
US20120148562A1 (en) * 2009-04-01 2012-06-14 Revance Therapeutics, Inc. Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
AU2010259986B2 (en) 2009-06-10 2015-04-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
AU2010265888A1 (en) 2009-06-25 2012-01-19 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
US10022083B2 (en) 2011-06-02 2018-07-17 Abdulmohsen E. A. H. Al-Terki Multiple oral and nasal surgical procedures method and kit
US8387798B1 (en) 2012-04-27 2013-03-05 Abdulmohsen E. A. H. Al-Terki Mutiple oral and nasal surgical procedures method and kit
FR2997304B1 (fr) 2012-10-26 2017-07-07 Isp Investments Inc Utilisation d’un extrait de lin, en tant qu’agent actif activateur de la synthese de peptides antimicrobiens
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
US20140242110A1 (en) * 2013-02-28 2014-08-28 Dt Scimed, Llc Dose, localization, and formulation of botulinum toxins in skin and muscle
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
RU2724545C2 (ru) 2015-09-17 2020-06-23 Контрафект Корпорейшн Полипептиды лизина, активные против грамотрицательных бактерий
US10105381B2 (en) * 2016-05-23 2018-10-23 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10144767B2 (en) * 2016-08-18 2018-12-04 Board Of Regents Of The University Of Nebraska Anti-microbial peptides and coatings
BR112019010131A2 (pt) * 2016-11-21 2019-10-08 Eirion Therapeutics Inc entrega transdérmica de agentes grandes
US12161703B2 (en) 2017-08-28 2024-12-10 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
CN107556374B (zh) * 2017-08-30 2020-02-07 四川大学 唾液富脯蛋白仿生防龋功能多肽、其衍生物和盐及其应用
CN107353334B (zh) * 2017-08-30 2020-02-07 四川大学 基于唾液富酪蛋白的仿生防龋多肽、其衍生物和盐及应用
JP7266202B2 (ja) * 2018-02-19 2023-04-28 株式会社ファンケル 化粧料及び抗炎症剤
NZ793134A (en) * 2020-04-08 2025-10-31 Amicrobe Inc Compositions and uses of locally applied synthetic amino acid polymers for prevention and treatment of viral infections
WO2025059665A1 (en) 2023-09-15 2025-03-20 Revance Therapeutics, Inc. Serial treatment with botulinum toxin for cervical dystonia
WO2025064729A1 (en) 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance
WO2025072381A1 (en) 2023-09-25 2025-04-03 Revance Therapeutics, Inc. Methods for determining influence of carrier peptide on the binding of a therapeutic protein to a cell membrane

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
AU4037793A (en) 1992-04-23 1993-11-29 Allelix Biopharmaceuticals Inc. Treatment of herpesvirus infection
CA2135642C (en) 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
CA2152373C (en) * 1993-10-22 1998-12-15 Michael Twist (Deceased) Treatment of cytomegalovirus infection
EP1600163B1 (en) 1993-12-28 2010-02-17 Allergan, Inc. Use of the neurotoxic component of botulinum toxins for the treatment of spastic muscle
US6232295B1 (en) 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
AU6940796A (en) * 1995-08-23 1997-03-19 University Of British Columbia, The Antimicrobial cationic peptides and methods of screening for the same
US6043218A (en) * 1996-10-22 2000-03-28 Medical University Of South Carolina Positively charged non-natural amino acids, methods of making thereof, and use thereof in peptides
GB9623051D0 (en) 1996-11-06 1997-01-08 Schacht Etienne H Delivery of DNA to target cells in biological systems
AU1818299A (en) * 1997-12-10 1999-06-28 Washington University Anti-pathogen system and methods of use thereof
JP2002508187A (ja) * 1997-12-12 2002-03-19 オニックス ファーマシューティカルズ，インコーポレイティド Ｐ５３＋新生細胞の選択的殺死及び診断
WO2000024419A1 (en) 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
JP2002531113A (ja) 1998-12-10 2002-09-24 ワシントン大学 蛋白質の形質導入システムおよびその使用法
JP2002533379A (ja) 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
US7056656B1 (en) * 1999-01-25 2006-06-06 University Of Medicine And Dentistry Of New Jersey Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
US20030236214A1 (en) * 1999-06-09 2003-12-25 Wolff Jon A. Charge reversal of polyion complexes and treatment of peripheral occlusive disease
US7008924B1 (en) * 1999-07-21 2006-03-07 Amgen, Inc. VGF fusion polypeptides
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6844324B1 (en) * 1999-11-12 2005-01-18 Massachusetts Institute Of Technology Modular peptide mediated intracellular delivery system and uses therefore
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20030215412A1 (en) * 2000-07-21 2003-11-20 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
AU2001284665B2 (en) * 2000-07-21 2006-06-08 Revance Therapeutics, Inc. Multi-component Biological Transport Systems
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6696038B1 (en) * 2000-09-14 2004-02-24 Expression Genetics, Inc. Cationic lipopolymer as biocompatible gene delivery agent
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7585834B2 (en) 2001-02-16 2009-09-08 The Board Of Trustees Of The Leland Stanford Junior University Transporters comprising spaced arginine moieties
JP2004536585A (ja) * 2001-05-09 2004-12-09 エール・ユニバーシティ トル／インターロイキン−１受容体アダプタータンパク質（ｔｉｒａｐ）
US7060498B1 (en) * 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
CA2469336C (en) * 2001-12-11 2013-06-11 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
WO2003072049A2 (en) 2002-02-21 2003-09-04 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
US20030215395A1 (en) * 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
JP4154218B2 (ja) * 2002-11-27 2008-09-24 寛紀 高麗 新規抗菌性ポリペプチドとその利用
IL153557A0 (en) * 2002-12-19 2003-07-06 Yitzchak Hillman Antibodies and antagonists to antimicrobial peptides for the purpose of treating, inhibiting and preventing auto immune diseases
WO2004056307A2 (en) * 2002-12-19 2004-07-08 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
EP1594969B1 (en) * 2003-02-01 2015-05-20 Janssen Sciences Ireland UC Active immunization to generate antibodies to soluble a-beta
US7482016B2 (en) * 2003-03-19 2009-01-27 The J. David Gladstone Institutes Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
MXPA06002828A (es) * 2003-09-12 2006-06-23 Univ British Columbia Efectores de determinacion de inmunidad innata.
JP2005120050A (ja) * 2003-10-20 2005-05-12 Toagosei Co Ltd 新規抗菌性ペプチドとその利用
EP2656859B1 (en) * 2004-03-03 2015-10-21 ReVance Therapeutics, Inc. Topical application and transdermal delivery of botulinum toxins
KR101284710B1 (ko) 2004-03-03 2013-07-23 레반스 테라퓨틱스, 아이엔씨. 국소 진단제 및 치료제의 수송을 위한 조성물 및 방법
DK1778720T3 (da) * 2004-08-18 2010-11-29 Novabiotics Ltd Antimikrobielle peptider omfattende et arginin- og/eller lysinholdigt motiv
WO2006050611A1 (en) 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
EP1656951A1 (en) * 2004-11-12 2006-05-17 Xigen S.A. Conjugates with enhanced cell uptake activity
EP1661912A1 (en) 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
JP4730584B2 (ja) * 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
JP2006238751A (ja) * 2005-03-02 2006-09-14 Toagosei Co Ltd ベロ毒素結合性を有する抗菌ペプチド及びその利用
US20090247464A1 (en) 2005-03-03 2009-10-01 Revance Therapeutics, Inc. Compositions and Methods for Topical Application and Transdermal Delivery of an Oligopeptide
CA2599017C (en) 2005-03-03 2014-08-12 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI0608951A2 (pt) 2005-03-30 2010-02-17 Revance Therapeutics Inc composições e método para o tratamento de acne
CA2629499A1 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
WO2008082889A2 (en) 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
NZ598159A (en) 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
ES2805225T3 (es) * 2007-07-26 2021-02-11 Revance Therapeutics Inc Péptidos antimicrobianos y composiciones de los mismos
EP3332805B1 (en) * 2008-12-31 2022-02-23 ReVance Therapeutics, Inc. Injectable botulinum toxin formulations

Also Published As

Publication number Publication date
KR20100047867A (ko) 2010-05-10
KR20150090268A (ko) 2015-08-05
JP6722241B2 (ja) 2020-07-15
JP5401457B2 (ja) 2014-01-29
ES2805225T3 (es) 2021-02-11
CN101842107B (zh) 2014-04-23
JP2020169190A (ja) 2020-10-15
US8623811B2 (en) 2014-01-07
AU2008278593A2 (en) 2011-05-12
PT3120862T (pt) 2020-06-25
BR122019000266B1 (pt) 2021-09-14
BR122019000258B1 (pt) 2021-09-14
CA2694046A1 (en) 2009-01-29
HUE031136T2 (en) 2017-07-28
JP2010534684A (ja) 2010-11-11
IL223785A (en) 2015-02-26
SI2178549T1 (sl) 2017-08-31
US20100215591A1 (en) 2010-08-26
ES2609914T3 (es) 2017-04-25
SG188128A1 (en) 2013-03-28
DK3120862T3 (da) 2020-06-22
BRPI0813627A2 (pt) 2014-12-23
EP3120862B1 (en) 2020-04-29
PT2178549T (pt) 2016-12-20
CA2694046C (en) 2023-09-12
EP2178549A4 (en) 2014-02-19
CR11239A (es) 2010-06-29
EP2178549B1 (en) 2016-09-14
EP2178549A1 (en) 2010-04-28
AU2008278593B2 (en) 2015-04-09
CY1123176T1 (el) 2021-10-29
IL223784A (en) 2015-02-26
CN101842107A (zh) 2010-09-22
PL2178549T3 (pl) 2017-03-31
EP3741380A1 (en) 2020-11-25
JP5965884B2 (ja) 2016-08-10
KR20170016031A (ko) 2017-02-10
LT2178549T (lt) 2017-01-25
BRPI0813627B1 (pt) 2021-09-14
MX2010000916A (es) 2010-06-02
KR101722038B1 (ko) 2017-04-03
AU2008278593A1 (en) 2009-01-29
KR101717275B1 (ko) 2017-03-16
HK1180237A1 (zh) 2013-10-18
DK2178549T3 (en) 2017-01-09
NZ582459A (en) 2012-05-25
CN102872447B (zh) 2015-09-30
CN102872447A (zh) 2013-01-16
JP2014076993A (ja) 2014-05-01
CO6260098A2 (es) 2011-03-22
JP2017002057A (ja) 2017-01-05
JP2019006791A (ja) 2019-01-17
EP3120862A1 (en) 2017-01-25
HRP20161722T1 (hr) 2017-02-10
WO2009015385A1 (en) 2009-01-29
KR20180031824A (ko) 2018-03-28
IL203173A (en) 2014-12-31
KR102088949B1 (ko) 2020-03-13

Similar Documents

Publication Publication Date Title
CY1123176T1 (el) Antimikpobiako πεπτιδιο και συνθεσεις αυτου
CY1121551T1 (el) Φαρμακευτικη ή καλλυντικη συνθεση για τη θεραπεια της αλωπεκιας
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
MX2020007944A (es) Nanocomplejos similares a los lípidos y sus usos.
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
CY1109385T1 (el) Αναστολεις γυρασης και χρησεις αυτων
NO20083245L (no) Sykliske antimikrobielle peptider
CY1115318T1 (el) Ισοκινολινο ρυθμιστες μεταφορεων κασετας συνδεσης ατρ
WO2011047868A3 (en) Peptides used in the treatment and/or care of the skin, mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions
DE50310516D1 (de) Fredericamycin-derivate
ATE533795T1 (de) Neutralisiertes kationisches polymer, zusammensetzung mit dem besagten polymer und kosmetisches behandlungsverfahren
UY26269A1 (es) Formulación de sal común y moxifloxacina
BR0011766A (pt) Misturas de micropigmentos
DE602006006308D1 (de) Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
ATE333863T1 (de) Zusammensetzungen enthaltend ein ethanolaminderivat sowie organische metallsalze
AU2020217620B2 (en) Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
BRPI0405939A (pt) Formulações antibacterianas de uso tópico
CY1107633T1 (el) Υδατικο φαρμακευτικο διαλυμα περιεχον οξυμεταζολινη και/ή ξυλομεταζολινη
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
BR0315437A (pt) Composição para o tratamento dos cabelos, usos da mesma e método para o tratamento dos cabelos
CY1107480T1 (el) Χρηση aivlosin για την θepαπευτικη αγωγη και προληψη λοιμωξεων lawsonia σε χοιρους
BRPI0411534A (pt) derivados de lincomicina com atividade antimicrobiana
ECSP045397A (es) 6-ALQUILIDEN-PENEMS BICÍCLICOS COMO INHIBIDORES DE LAS b-LACTAMASAS
ES2178761T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de infe cciones cutaneas.